Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2006

View Archived Issues

PowderMed's vaccine approach achieves crossprotection for influenza and drifting strains

Nuvo Research acquires fqubed

IDM Pharma completes sale of non-core assets to Pharmexa

Closing of Pain Therapeutics and King's strategic alliance

pSivida completes acquisition of Control Delivery Systems

MAA completed for Genasense plus chemotherapy in malignant melanoma

InterMune completes sale of Infergen to Valeant

Amarin licenses LAX-202 rights for MS fatigue to Multicell Technologies

Anturol completes phase II dose-ranging study

U.S. Navy to receive defense appropriation for Hemopure R&D

Inex shareholders to vote on Targeted Immunotherapy spin-out

FDA clears NT-proBNP test for new risk stratification use

New quinolone antibacterials emerge from Pfizer R&D

sanofi-aventis prepares and tests new histamine H3 receptor antagonists

Preclinical and clinical erythropoietic activity of CNTO-528

Method for diagnosis/prognosis of wound infection claimed in Ethicon patent

Albaconazole superior to fluconazole in phase II vulvovaginal candidiasis trial

New data support Factor Xa inhibition for thromboprophylaxis

Tamoxifen efficacy in breast cancer affected by CYP450 2D6 genotype

Novel HIV integrase inhibitors designed by Bioflexis

Immunosuppressive effects of NK-026680 useful for acute GVHD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...